<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: <z:hpo ids='HP_0001639'>Hypertrophic cardiomyopathy</z:hpo> (HCM) is a frequent cause of <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> (SCD) due to exercise-related <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> (ERVA); however the pathological substrate is uncertain </plain></SENT>
<SENT sid="1" pm="."><plain>The aim was to determine the prevalence of ERVA and their relation with <z:mp ids='MP_0003045'>fibrosis</z:mp> as determined by cardiac magnetic resonance imaging (CMR) in carriers of an HCM causing mutation </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We studied the prevalence and origin of ERVA and related these with <z:mp ids='MP_0003045'>fibrosis</z:mp> on CMR in a population of 31 HCM mutation carriers </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: ERVA occurred in seven patients (23%) who <z:hpo ids='HP_0000001'>all</z:hpo> showed evidence of <z:mp ids='MP_0003045'>fibrosis</z:mp> (100% ERVA(+) vs. 58% ERVA(-), p = 0.04) </plain></SENT>
<SENT sid="4" pm="."><plain>No <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> or <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> occurred </plain></SENT>
<SENT sid="5" pm="."><plain>In patients with ERVA, the extent of <z:mp ids='MP_0003045'>fibrosis</z:mp> was significantly larger (8 ± 4% vs. 3 ± 4%, p = 0.02) </plain></SENT>
<SENT sid="6" pm="."><plain>ERVA originated from areas with a high extent of <z:mp ids='MP_0003045'>fibrosis</z:mp> or regions directly adjacent to these areas </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: ERVA in HCM mutation carriers arose from the area of <z:mp ids='MP_0003045'>fibrosis</z:mp> detected by CMR; ERVA seems closely related to <z:mp ids='MP_0003141'>cardiac fibrosis</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain><z:mp ids='MP_0003045'>Fibrosis</z:mp> as detected by CMR should be evaluated as an additional risk factor to further delineate risk of SCD in carriers of an HCM causing mutation </plain></SENT>
</text></document>